PCRX Pacira BioSciences, Inc. Insider Trading

CFO Cross Shawn sold 25,000 shares (25.0K shares) for $626,751.44 ($626.8K) across 2 separate sales on 12/09-12/10 at blended average price $25.07

Chief Financial Officer Shawn Cross executed 2 separate sales totaling 25,000 shares for $626,751.44, reducing his holdings by 30.8% from 81,250 to 56,250 shares. The sales occurred at blended average price $25.07, modestly below the current price of $25.73. Pacira trades at a P/E of 51.46 with full-year net income negative, though the latest quarterly net income was $5,432,000 on revenue of $179,516,000. The 30-day stock performance is +6.7%, positioning this sale in a period of recent gains following a 90-day decline of -5.1%.

Director Bigal Marcelo buys 1,512 shares of PCRX at $13.25 as stock -63.1% from 52-week high; cluster of 4 other insiders also bought within 14 days.

Director Bigal Marcelo purchased 1,512 shares at $13.25 on 2024-08-16, increasing his holdings by 17.5% to 10,142 shares total. The purchase occurred after a sharp drawdown: the stock is -63.1% from its 52-week high and down 54.8% over the past 90 days, creating a depressed valuation context. Notably, 4 other insiders also bought within the past 14 days, indicating a clustering pattern of insider accumulation during weakness. The company's fundamentals remain intact with $178.0M revenue and $18.9M net income in the latest quarter, suggesting the buying may reflect conviction in value at depressed prices rather than concern about near-term prospects.

Director Brege Laura bought 1,000 PCRX shares at $12.81 on 2024-08-16; 4 other insiders also bought within 14 days as stock down -54.8% over 90 days

Director Laura Brege purchased 1,000 shares at $12.81, increasing her position from 16,552 to 17,552 shares. This transaction is noteworthy in context: the stock has fallen -54.8% over the past 90 days and -27.8% in the past 30 days, trading at $13.98 versus a 52-week high of $37.88. Critically, a cluster pattern emerged with 4 other insiders also buying within the past 14 days, suggesting coordinated or simultaneous interest at depressed price levels. The company maintains modest fundamentals with $178.0M quarterly revenue and $18.9M net income, and trades at a P/E of 10.13 with a market cap of $644.9M. The convergence of multiple insider purchases during a sharp selloff merits investor attention.

Director Yang buys 2,000 shares at $12.90 as PCRX stock falls -67.1% from 52-week high; 3 other insiders bought within 14 days

Michael J. Yang, a director, purchased 2,000 shares at $12.90, representing a 38.2% increase to his holdings of 7.2K shares. This transaction occurs within a 14-day window containing three other insider purchases at the same company, forming a cluster buy pattern. The stock has declined substantially, trading -67.1% from the 52-week high of $37.88, -41.5% over 30 days, and -60.4% over 90 days, and currently sits at $12.47, just above the 52-week low of $11.70. While fundamentals show positive net income of $18.9M on revenue of $178.0M and a low P/E of 9.04, the concurrent buying by multiple insiders during a sharp price decline merits investor scrutiny to distinguish between opportunistic accumulation at depressed prices versus broader concerns about valuation or near-term catalysts that insiders may perceive.

CEO Lee Frank D. bought 8,264 shares of PCRX at $12.10; stock down -67.4% from 52-week high amid cluster buy pattern

Lee Frank D., Chief Executive Officer of Pacira BioSciences, purchased 8,264 shares at $12.10 on 2024-08-12, increasing his holdings from 99,520 to 107,784 shares. This transaction occurs within a cluster pattern: 2 other insiders also bought within the past 14 days, suggesting coordinated confidence at depressed valuations. The stock is trading at $12.40 currently, down -67.4% from its 52-week high of $38.06 and down -58.8% over the past 90 days, yet the company maintains solid fundamentals with Revenue $178,023,000.00 and Net income $18,886,000.00, trading at a P/E of 8.99. The convergence of executive capital commitment alongside peer insider purchases during a sharp equity drawdown warrants investor attention to what prompted this accumulation pattern and whether it reflects conviction in recovery prospects or response to near-term operational concerns.

Director Bigal Marcelo buys 3,400 shares of PCRX at $12.01; stock down 60.1% in 90 days; cluster of 2 other insider buys within 14 days.

Bigal Marcelo purchased 3,400 shares at $12.01, increasing his holdings by 65.0% to 8,630 shares total. The timing coincides with a cluster pattern: 2 other insiders also bought within the past 14 days, suggesting coordinated or simultaneous conviction at current price levels. The stock has experienced severe price deterioration—down 60.1% over 90 days and 67.8% from its 52-week high of $38.18—creating a significant gap between the director's entry point and peak valuation. Against this backdrop, the company maintains modest fundamentals with annual revenue growth of 1.2% and a P/E of 8.91, leaving unclear whether the cluster buy reflects oversold opportunity identification or acquisition by insiders at depressed levels following a sharp drawdown.

Director Mark Froimson buys 1.4K shares of PCRX at $11.58 as stock down 67.8% from 52-week high; cluster buy pattern underway.

Director Froimson purchased 1,400 shares at $11.58 on 2024-08-12, increasing his holdings to 14,473 shares and representing a 10.7% increase from his prior position of 13,073 shares. The purchase occurs as Pacira trades at a significant discount to its 52-week high of $38.18 — approximately 67.8% below the peak — and has declined 43.5% over the past 30 days and 60.1% over the past 90 days. The discretionary open-market purchase is notable because 2 other insiders have also bought within the past 14 days, forming a cluster buy pattern rather than an isolated transaction. The company maintains profitability with net income of $18,886,000.00 on quarterly revenue of $178,023,000.00, and trades at a modest P/E of 8.91, though annual revenue growth stands at only 1.2%.